News J&J files intravesical bladder cancer drug TAR-200 in US Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).
News Lilly nets Scorpion cancer drug in $2.5bn licensing deal Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.
News GSK confirms plan to buy cancer firm IDRx for $1bn GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.
News World's largest proteomics trial launched by UK Biobank A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today.
News Is GSK prepping a $1bn takeover bid for IDRx? GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.
News Galapagos unveils plan to split, hiving off its drugs unit Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.
News France 'first EU country to cover obesity drugs' France's Health Minister has said that the country is the first in the EU to provide reimbursement coverage for GLP-1 weight-loss therapies.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.